Federal Register / Vol. 62, No. 56 / Monday, March 24, 1997 / Notices 13905

The underlying purpose of 10 CFR

50.82(b)(6) is to describe the

requirements that must be met for

license termination, one of which is that

the results of the terminal survey and

other documentation show that the

facility and site meet the requirements

for release. These survey results and

documentation form part of the basis for

terminating the license. In this case, the

remaining reactor components (the

facility) will be released, but the site

will not be released. Because the site

will continue to be subject to the NRC

license for the TRIGA reactor,

application of the rule that the terminal

survey and other documentation must

show that the site is suitable for release

is not necessary in order to terminate

the license.

IV

For the foregoing reasons, the NRC

staff has concluded that not requiring a

terminal radiation survey and associated

documentation that demonstrate that

the site is suitable for release as a

condition of license termination will not

present an undue risk to public health

and safety and is consistent with the

common defense and security. The NRC

staff has determined that there are

special circumstances present, as

specified in 10 CFR 50.12(a)(2), in that

application of part of 10 CFR

50.82(b)(6)(ii) is not necessary in order

to achieve the underlying purpose of

this regulation.

Accordingly, the Commission has

determined that, pursuant to 10 CFR

50.12(a), an exemption is authorized by

law, will not endanger life or property

or common defense and security, and is

otherwise in the public interest.

Therefore, the Commission hereby

grants an exemption from the

requirements of 10 CFR 50.82(b)(6)(ii)

that a terminal radiation survey and

associated documentation demonstrates

that the site is suitable for release are

needed as a condition of Operating

License No. R–25 termination.

Pursuant to 10 CFR 51.32, the

Commission has determined that the

granting of this exemption will not have

a significant effect on the quality of the

human environment (62 FR 11936).

For further details with respect to this

action, see (1) the application for

termination of Amended Facility

Operating License No. R–25, dated July

17, 1990, as supplemented; (2) the

Commission’s safety evaluation related

to the termination of the license; (3) the

environmental assessment and finding

of no significant impact; and (4) the

Commission’s Order terminating

Amended Facility Operating License

No. R–25. Each of these items is

available for public inspection at the

Commission’s Public Document Room,

2120 L Street, NW., Washington, D.C.

20037.

Copies of items (2), (3), and (4) may

be obtained upon receipt of a request

addressed to the U.S. Nuclear

Regulatory Commission, Washington,

D.C. 20555–0001, Attention: Director,

Division of Reactor Program

Management.

This exemption is effective upon

issuance.

Dated at Rockville, Maryland, this 14th day

of March 1997.

For the Nuclear Regulatory Commission.

Samuel J. Collins,

Director, Office of Nuclear Reactor

Regulation.

[FR Doc. 97–7338 Filed 3–21–97; 8:45 am]

BILLING CODE 7590–01–P

Nominations of New Members of the

Advisory Committee on the Medical

Uses of Isotopes

AGENCY: U.S. Nuclear Regulatory

Commission

ACTION: Call for nominations.

SUMMARY: The U.S. Nuclear Regulatory

Commission is inviting nominations for

three positions on the Advisory

Committee on the Medical Uses of

Isotopes (ACMUI) to fill current and

upcoming committee vacancies. One

position is for a physician practicing

nuclear cardiology. The second position

is for a patients’ rights and care

advocate. The third position is for an

individual with State or local

government perspective.

DATES: Nominations are due May 23,

1997.

ADDRESSES: Submit nominations to: The

Office of Personnel, Attn: Ms. Jude

Himmelberg, Mail Stop T2D32, U.S.

Nuclear Regulatory Commission,

Washington, DC 20555.

FOR FURTHER INFORMATION CONTACT:

William B. McCarthy, Office of Nuclear

Material Safety and Safeguards, U.S.

Nuclear Regulatory Commission,

Washington, DC 20555, Telephone:

301–415–7894.

SUPPLEMENTARY INFORMATION: The

ACMUI advises NRC on policy and

technical issues that arise in regulating

the medical use of byproduct material

for diagnosis and therapy.

Responsibilities include providing

guidance and comments on changes in

NRC rules, regulations, and guides

concerning medical use; evaluating

certain non-routine uses of byproduct

material for medical use; and providing

technical assistance in licensing,

inspection, and enforcement cases.

Committee members possess the

medical and technical skills needed to

address evolving issues. Currently, the

ACMUI membership consists of: (a)

three practicing physicians; (b) a

physician representing the U.S.

Department of Health and Human

Services, Food and Drug

Administration; (c) a nuclear

pharmacist; (d) two medical physicists

(nuclear medicine and therapy); (e) a

health care administrator; (f) a certified

medical dosimetrist; and (g) a patients’

rights and care advocate (whose term

expires September 30, 1997). Presently,

the specialties of the physicians on the

ACMUI are: therapeutic radiology, with

expertise in teletherapy and

brachytherapy (two), and nuclear

medicine research (one). The staff is in

the process of finalizing the

appointment of a nominee for the

position of nuclear medicine physician.

The U.S. Nuclear Regulatory

Commission is inviting nominations for

three positions on the Advisory

Committee on the Medical Uses of

Isotopes (ACMUI). One position is for a

physician practicing nuclear cardiology.

The second position is for a patients’

rights and care advocate. The third

position is for an individual with State

or local government perspective.

Nominees must include four copies of

their resumes, describing their

educational and professional

qualifications, and provide their current

addresses and telephone numbers.

All new committee members will

serve 3-year terms, with possible

reappointment to an additional 3-year

term.

Nominees must be U.S. citizens and

be able to devote approximately 80

hours per year to committee business.

Members will be compensated and

reimbursed for travel (including per

diem in lieu of subsistence), secretarial,

and correspondence expenses.

Nominees will undergo a security

background check and will be required

to complete financial disclosure

statements, to avoid conflict-of-interest

issues.

Dated at Rockville, Maryland, this 18th day

of March, 1997.

For the U.S. Nuclear Regulatory

Commission.

Andrew L. Bates,

Advisory Committee Management Officer,

Office of the Secretary of the Commission.

[FR Doc. 97–7316 Filed 3–21–97; 8:45 am]

BILLING CODE 7590–01–P